Skip to content

Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults

68
Academic
Chimera Difficulty Score
a synthesis of Flesch-Kincaid, Coleman-Liau, SMOG, and Dale-Chall readability metrics
Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults Published May 6, 2026 N Engl J Med 2026;394:1803-1813 DOI: 10.1056/NEJMoa2516491 Abstract Background Seasonal influenza causes substantial illness and death in adults 50 years of age or older, even with current vaccines. An investigational messenger RNA (mRNA)–based vaccine called mRNA-1010 encodes hemagglutinin glycoproteins from...
**ACADEMIC MODE** This study presents a robust phase 3 trial of mRNA-1010, an mRNA-based influenza vaccine, demonstrating its superiority over standard-dose vaccines in adults aged 50 and older. The methodology is sound, with a large sample size (40,703 participants), double-blinding, and active controls, which strengthens the internal validity. The primary endpoint—RT-PCR-confirmed influenza-like illness—is clinically relevant, and the hierarchical testing for noninferiority, superiority, and h...